Table 2.
Concordance between assigned Kidney Function Categories using measured GFR versus Estimated GFR equations in Selected Subgroups
| Concordant (%) Kappa (95% CI) |
|||
|---|---|---|---|
|
|
|||
| CKD-EPI | MDRD Study | Cockcroft-Gault | |
| Overalla | 79 0.65 (0.55, 0.74) |
71 0.55 (0.45, 0.65) |
77 0.61 (0.52, 0.71) |
| Tenofovir Use/Exposure | |||
| Yes | 80 0.63 (0.51, 0.75) |
70 0.50 (0.38, 0.62) |
78 0.59 (0.47, 0.71) |
| No | 77 0.67 (0.52, 0.82) |
72 0.62 (0.46, 0.77) |
75 0.64 (0.49, 0.79) |
| Age group (years) | |||
| ≤50 | 84 0.67 (0.54, 0.80) |
75 0.55 (0.42, 0.68) |
81 0.62 (0.48, 0.75) |
| >50 | 69 0.57 (0.41, 0.74) |
63 0.51 (0.34, 0.67) |
68 0.56 (0.40, 0.72) |
| Sex | |||
| Women | 80 0.71 (0.56, 0.87) |
69 0.57 (0.40, 0.74) |
78 0.69 (0.54, 0.85) |
| Men | 79 0.60 (0.47, 0.73) |
72 0.52 (0.40, 0.65) |
76 0.57 (0.44, 0.69) |
| Race | |||
| African Americans | 84 0.74 (0.63, 0.85) |
79 0.67 (0.55, 0.79) |
74 0.60 (0.48, 0.73) |
| White or other | 74 0.54 (0.37, 0.70) |
63 0.42 (0.27, 0.57) |
79 0.63 (0.48, 0.78) |
| BMI group (kg/m2) | |||
| <22 | 66 0.54 (0.32, 0.76) |
66 0.54 (0.32, 0.76) |
54 0.43 (0.22, 0.64) |
| 22-30 | 82 0.69 (0.57, 0.81) |
74 0.58 (0.46, 0.70) |
79 0.64 (0.51, 0.76) |
| >30 | 81 0.63 (0.39, 0.86) |
67 0.44 (0.20, 0.68) |
89 0.71 (0.48, 0.95) |
| HIV RNA viral load (copies/mL) | |||
| Undetected | 76 0.63 (0.50, 0.76) |
66 0.53 (0.40, 0.66) |
79 0.68 (0.57, 0.80) |
| <1000 | 84 0.63 (0.44, 0.81) |
79 0.53 (0.34, 0.73) |
79 0.53 (0.34, 0.73) |
| ≥1000 | 79 0.66 (0.30, 1.00) |
79 0.66 (0.30, 1.00) |
64 0.49 (0.11, 0.86) |
Abbreviations: CKD-EPI, Chronic Kidney Disease Epidemiology collaboration; MDRD Study, Modification of Diet in Renal Disease Study; BMI, body mass index
p<0.003 for comparison for the difference in concordance of each equation to measured GFR.
Concordance for MDRD Study equation and CKD-EPI equations were statistically different (p=0.0006), while Cockcroft-Gault concordance was not statistically different to MDRD study equation or CKD-EPI (p > 0.09 for both)
Tenofovir (Viread®)
Kidney Function categories from Food and Drug Administration. Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function — Study Design, Data Analysis, and Impact on Dosing and Labeling. Rockville: U.S. Department of Health and Human Services; May 1998 [22]